Panel discussion: developing successful advanced therapy partnerships

Collaboration is key in progressing the cell and gene therapy industry from research level to commercialization. In such a complex and rapidly evolving industry, how can we build successful partnerships in advanced therapies? How do you build a trust-based partnership from a commercial transaction? Our panel of experts explore this topic in depth, from balancing competing interests to building trust.

Watch the panel to find out more.

This webinar was recorded on 5 July 2022.

What will you learn?Who may this interest?Speakers

What will you learn?

  • Considerations when working with CMO/CDMOs
  • Leveraging external knowledge for internal improvement
  • Outsourcing vs partnering from investigation to commercialization

Who may this interest?

  • Researchers and developers of advanced therapies
  • Other stakeholders in developing advanced therapies

Speakers

Brian Mullan
Chief Technical Officer
Yposkesi, an SK pharmteco (France)

Brian Mullan has been Yposkesi’s Chief Technical Officer since October 2020. With over 20 years’ experience working for multinational pharmaceutical companies, Brian has held leadership roles in late phase process development, validation, submission, launch and commercial supply for therapeutic monoclonal antibodies. He spent the last nine years at Novartis, as a Global CMC Product Lead and then Head of Manufacturing Science & Technology. Prior to that, he worked at Eli Lilly (IN, USA), Centocor Biologics (MO, USA) and Sanofi-Aventis (France). Brian holds a PhD in Viral Genetics and an MBA.

 

Jeff Liter
CEO
Luminary Therapeutics (MN, USA)

Jeff is a seasoned CEO with a proven track record at profitably growing emerging companies and business divisions. He has raised over US$10M in seed capital from angel investors to start four different companies which he then led to becoming profitable or acquired. At his time at Progenitor Cell Therapy, LLC (NJ, USA) as their COO, he supported over 20 clinical trials in the cell and gene therapy field. These trials ranged from Phase I to Phase III pivotal trials. He was responsible for tech transferring Kite’s (CA, USA) T-Cell therapy out of the NIH, and Novartis’ (Switzerland) cell therapy and Adaptimmume’s (UK) cell therapy, both out of University of Pennsylvania (USA).

 

Joe Garrity
Director, Commercial Development; Autologous Cell Therapy
Lonza (Switzerland)

Joe Garrity is the Director, Commercial Development for Autologous Cell Therapy, at Lonza Cell and Gene Technologies. Joe works within the global cell and gene business unit and leadership team to enable strategic development and growth of the autologous modality in Lonza CGT, as well as works with operations, development, and quality teams to streamline the clinical and commercial manufacturing services and offers provided by Lonza. Joe has an educational background in biochemistry and a professional background of over 10 years within the cell and gene CDMO space and has covered multiple positions within development, operations, and business functions.

 

Nicole Faust
CEO
CEVEC Pharmaceuticals (Germany)

Nicole Faust is the CEO of CEVEC Pharmaceuticals. Until 2019 she was also Chief Scientific Officer of the company, responsible for directing CEVEC´s technology focus towards gene therapy and establishing the company´s viral vector production platforms. Before joining CEVEC in 2011, she held scientific management positions with Lonza Cologne and Artemis Pharmaceuticals, now Taconic Biosciences (Germany). Nicole holds a PhD in cell and molecular biology from University of Freiburg and an MBA from Educatis University, Switzerland. She is a member of the American Society for Gene and Cell Therapy and currently Chair of the Gene Therapy Advisory Committee of the Alliance for Regenerative Medicine (ARM).

 

Miguel Forte
CEO
Bone Therapeutics

Miguel Forte has over 20 years professional activity in clinical, academic and pharmaceutical industry environments, was previously CEO of Zelluna Immunotherapy (Norway), Vice-President Global Medical Affairs Inflammation at UCB (UK), Chief Medical Officer (CMO) at TxCell (now a subsidiary of Sangamo Therapeutics, France) and held a senior position at the European Medicines Agency (EMA). Dr Forte graduated in Medicine from the University of Lisbon (Portugal), specializing in infectious diseases. He then obtained a PhD in Immunology at the University of Birmingham (UK). He is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians, UK and Associate Professor in Health Sciences and Pharmacy at the University of Lisbon. He is currently serving as Chief Commercialization Officer and Chair of the Commercialization Committee of the International Society of Cellular Therapy (ISCT).

In association with